Threshold Pharmaceuticals Rises on Hope for Cancer Drug
Shares of Threshold Pharmaceuticals (NASDAQ:THLD) are rising after the company’s development partner Merck KGaA (PINK:MKGAY) of Germany said it is advancing a drug for pancreatic cancer into a large late-stage human study. Merck sends Threshold a $30 million milestone payment as part of an agreement announced in February of last year. The drug TH-302 is being tested with an older chemotherapy gemcitabine to treat advanced pancreatic cancer a disease that leaves patients little hope for surviving. The partnership with Merck is potentially worth $525 million to Threshold if the product is ever approved and meets sales goals. Threshold has ...
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here